|
Gilead (GILD): New potential in 4-in-1 HIV drug |
|
| Nov 05, 2009 06:10 PM UTC |
|
Tracked Blogger
|
Via BloggingStocks:
Filed under: Newsletters, Gilead Sciences (GILD), Stocks to Buy "Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe. The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill. "The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion. Continue reading Gilead (GILD): New potential in 4-in-1 HIV drug Gilead (GILD): New potential in 4-in-1 HIV drug originally appeared on BloggingStocks on Thu, 05 Nov 2009 13:10:00 EST. Please see our terms for use of feeds. Permalink | Email this | Comments
Read the rest of original post »
|
Be the first to comment on this story and earn 2 points.
|
|
IN THE PRESS |
|
|
|
|
|
|
| About | RSS | Feedback | Contact Us | Terms of Service | Privacy |
© 2009 FinancialContent Services, Inc. |
|
Data powered by FinancialContent. All Rights Reserved. Quotes delayed at least 20 minutes unless otherwise indicated. |
|
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. |
